16 results
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
, our board of directors has determined that Michael Jerman is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K
8-K
EX-99.1
MIRA
Mira Pharmaceuticals Inc
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
Substances Act (CSA) and its governing regulations.
Dr. Adam Kaplin, MD, PhD, MIRA’s President and Chief Scientific Officer and an esteemed expert
8-K
EX-1.1
MIRA
Mira Pharmaceuticals Inc
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
qualifies as an “audit committee financial expert,” as such term is defined in Item 407 of Regulation S-K and the listing rules of the Exchange … of the board of directors qualifies as an “audit committee financial expert”, as such term is defined in Item 407 of Regulation S-K and the listing
424B4
MIRA
Mira Pharmaceuticals Inc
4 Aug 23
Prospectus supplement with pricing info
1:01pm
executive and global medical expert and has extensive experience in providing monitoring and oversight for ongoing clinical trials including both adult … is an audit committee financial expert within the meaning of Item 407(d) of Regulation S-K under the Securities Act.
The audit committee’s main purpose
424B1
23lpgv93
4 Aug 23
Prospectus with pricing info
12:59pm
S-1
EX-99.1
oor3h
29 Jun 23
IPO registration
4:39pm
S-1
z4frykw4iw7zyngoh1f
29 Jun 23
IPO registration
4:39pm
DRS/A
ata1sap kjfr7sq00
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-99.1
qcpc28pjozu w6sst
8 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
w4sh41k75
2 May 23
Draft registration statement (amended)
12:00am
DRS
rxw9 7q75f1t8ju0
29 Jun 22
Draft registration statement
12:00am
- Prev
- 1
- Next